There are supply disruptions affecting various strengths of the following medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD):

·       Methylphenidate:

·       Equasym XL^® 10, 20 and 30 mg capsules

·       Xaggitin XL^® 18 and 36 mg prolonged-release tablets

·       Concerta XL^® 54 mg prolonged-release tablets

·       Xenidate XL^® 27 mg prolonged-release tablets

·       Lisdexamfetamine: 

·       Elvanse^® 20, 30, 40, 50, 60 and 70 mg capsules

·       Elvanse^® Adult 30, 50, and 70 mg capsules

·       Guanfacine:

·       Intuniv^® 1, 2, 3 and 4 mg prolonged-release tablets

The supply disruption of these products is caused by a combination of manufacturing issues and an increased global demand.

Other ADHD products remain available but cannot meet excessive increases in demand.

At present, the supply disruptions are expected to resolve at various dates between October and December 2023.

This National Patient Safety Alert provides further background and clinical information and actions for providers.